Real-world evidence of the use of glucocorticoids for severe COVID-19

Introduction: Currently, only glucocorticoids have proved to impact adverse outcomes in COVID-19. However, their risk/benefit balance remains inconclusive and populations’ characteristics should be considered. Objective: The objective was to evaluate the real-life use of glucocorticoids in patients...

Full description

Saved in:
Bibliographic Details
Published in:Therapeutic advances in endocrinology and metabolism 2022-01, Vol.13, p.20420188211072704
Main Authors: Albarrán-Sánchez, Alejandra, Ramírez-Rentería, Claudia, Mercado, Moisés, Sánchez-García, Miriam, de Jesús Barrientos-Flores, Corazón, Ferreira-Hermosillo, Aldo
Format: Article
Language:English
Subjects:
Comorbidity
Confidence intervals
Coronaviruses
COVID-19
Data analysis
Dexamethasone
Diabetes
Diabetes mellitus
Epidemiology
Glucocorticoids
Hypertension
Laboratory tests
Methylprednisolone
Mortality
Original Research
Patients
Polymerase chain reaction
Population studies
Prednisolone
Recovery
Severe acute respiratory syndrome coronavirus 2
Steroid hormones
Steroids
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction: Currently, only glucocorticoids have proved to impact adverse outcomes in COVID-19. However, their risk/benefit balance remains inconclusive and populations’ characteristics should be considered. Objective: The objective was to evaluate the real-life use of glucocorticoids in patients with severe COVID-19 hospitalized in a third-level referral center and to determine the type, accumulated doses, and the in-hospital outcomes related with their use. Methods: We evaluated a retrospective cohort of 737 patients with criteria for severe COVID-19 and a positive polymerase chain reaction (PCR) test for SARS-CoV-2. We extracted data for epidemiological analysis, medical history, and medications, as well as baseline laboratory tests. Data were analyzed using SPSS 21.0 and nonparametric tests, medians, and interquartile ranges (IQR). A p 675 mg of prednisolone). Conclusion: The use of steroids in severe COVID-19 reduces mortality only at the dose proposed in the RECOVERY study in the younger population. No benefit of the use of steroids was observed in patients with older age or higher number of comorbidities.
ISSN:2042-0188
2042-0196
DOI:10.1177/20420188211072704